NCT02231021View on ClinicalTrials.gov

The Practical Evidence of Antidiabetic Combination Therapy in Korea

PHASE4CompletedINTERVENTIONAL
Enrollment

216

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

October 22, 2018

Study Completion Date

January 28, 2019

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

alogliptin

alogliptin 25 mg add-on background medication metformin

DRUG

Pioglitazone

pioglitazone 30 mg add-on background medication metformin

DRUG

alogliptin + pioglitazone

alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin

Trial Locations (1)

137-701

Seoul St Mary's Hospital, The Catholic University of Korea, Seoul

Sponsors

Collaborators (1)

Takeda
All Listed Sponsors
collaborator

Takeda

INDUSTRY

lead

Kun-Ho Yoon

OTHER

NCT02231021 - The Practical Evidence of Antidiabetic Combination Therapy in Korea | Biotech Hunter | Biotech Hunter